Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 750 participants.

Also called NCT07449910

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 750 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07449910
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07449910. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-17 (anticipated); primary completion 2027-08-17 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
Condition
Acute Ichemic Stroke
Condition
Anterior Cerebral Artery Stroke
Condition
Baricitinib
Intervention (Drug)
2mg Baricitinib
Intervention (Drug)
4mg Baricitinib
Intervention (Drug)
Placebo
Intervention (Other)
Guideline-based therapy
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China (class: other)

Record details

Record id
cardio:ct-nct07449910
Content hash
60b0bcb518203649cbc8d7498a63deffbb7e47fc2788aff1186718f3b65b1034